Cargando…

A Heterologous Prime/Boost Vaccination Strategy Enhances the Immunogenicity of Therapeutic Vaccines for Hepatitis C Virus

Background. We explored the concept of heterologous prime/boost vaccination using 2 therapeutic vaccines currently in clinical development aimed at treating chronically infected hepatitis C virus (HCV) patients: prime with a DNA-based vaccine expressing HCV genotype 1a NS3/4A proteins (ChronVac-C) a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fournillier, Anne, Frelin, Lars, Jacquier, Emilie, Ahlén, Gustaf, Brass, Anette, Gerossier, Estelle, Holmström, Fredrik, Broderick, Kate E., Sardesai, Niranjan Y., Bonnefoy, Jean-Yves, Inchauspé, Geneviève, Sällberg, Matti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2013
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749006/ https://www.ncbi.nlm.nih.gov/pubmed/23776192 http://dx.doi.org/10.1093/infdis/jit267

Ejemplares similares

Functional Aspects of Intrahepatic Hepatitis B Virus-specific T Cells Induced by Therapeutic DNA Vaccination
por: Brass, Anette, et al.
Publicado: (2015)

Functional differences in hepatitis C virus nonstructural (NS) 3/4A- and 5A-specific T cell responses
por: Holmström, Fredrik, et al.
Publicado: (2016)

A targeted controlled force injection of genetic material in vivo
por: Ahlén, Gustaf, et al.
Publicado: (2016)

Therapeutic DNA Vaccination Using In Vivo Electroporation Followed by Standard of Care Therapy in Patients With Genotype 1 Chronic Hepatitis C
por: Weiland, Ola, et al.
Publicado: (2013)

Immune-mediated effects targeting hepatitis C virus in a syngeneic replicon cell transplantation mouse model
por: Levander, Sepideh, et al.
Publicado: (2018)

A small step closer to the Holy Grail of DNA vaccines: undisputed clinical benefit in humans
por: Frelin, Lars, et al.
Publicado: (2009)

The SARS-CoV-2 N Protein Is a Good Component in a Vaccine
por: Ahlén, Gustaf, et al.
Publicado: (2020)

Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections
por: Burm, Rani, et al.
Publicado: (2023)

Heterologous prime boost COVID 19 vaccination
por: Launay, O., et al.
Publicado: (2022)

Long-term functional duration of immune responses to HCV NS3/4A induced by DNA vaccination
por: Ahlén, G, et al.
Publicado: (2014)

Editorial: HBV—the naked truth?
por: Pasetto, Anna, et al.
Publicado: (2019)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
por: Goh, Yun Shan, et al.
Publicado: (2022)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
Publicado: (2023)

Generation of T-cell receptors targeting a genetically stable and immunodominant cytotoxic T-lymphocyte epitope within hepatitis C virus non-structural protein 3
por: Pasetto, Anna, et al.
Publicado: (2012)

Evaluation of heterologous prime-boost vaccination strategies using chimpanzee adenovirus and modified vaccinia virus for TB subunit vaccination in rhesus macaques
por: Vierboom, Michel P. M., et al.
Publicado: (2020)

Potency of an HIV-SAM™ vaccine in a heterologous prime-boost vaccination regimen
por: Banerjee, K, et al.
Publicado: (2012)

Heterologous Prime-Boost Vaccination with Commercial FMD Vaccines Elicits a Broader Immune Response than Homologous Prime-Boost Vaccination in Pigs
por: Kim, Jaejo, et al.
Publicado: (2023)

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
por: Nguyen, Thuy Trang, et al.
Publicado: (2022)

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
por: Shaw, Robert H, et al.
Publicado: (2021)

Heterologous prime-boost vaccination against COVID-19: is it safe and reliable?
por: Choudhary, Om Prakash, et al.
Publicado: (2021)

A universal SARS‐CoV DNA vaccine inducing highly cross‐reactive neutralizing antibodies and T cells
por: Appelberg, Sofia, et al.
Publicado: (2022)

The efficacy of the prime-boost regimen for heterologous infectious bronchitis vaccines mandates the administration of homologous vaccines
por: Al-Kubati, Anwar A. G., et al.
Publicado: (2022)

Exploring heterologous prime-boost vaccination approaches to enhance influenza control in pigs
por: Li, Chong, et al.
Publicado: (2020)

Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV
por: Chapman, Ros, et al.
Publicado: (2021)

Is heterologous prime-boost COVID-19 vaccination a concern or an opportunity for Ethiopia?
por: Gelanew, Tesfaye, et al.
Publicado: (2023)

Heterologous prime-boost with the mRNA-1273 vaccine among CoronaVac-vaccinated healthcare workers in Indonesia
por: Santi, Theresia, et al.
Publicado: (2022)

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials
por: Brown, Scott A., et al.
Publicado: (2010)

Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates
por: Bolton, Diane L., et al.
Publicado: (2012)

Blocking Entry of Hepatitis B and D Viruses to Hepatocytes as a Novel Immunotherapy for Treating Chronic Infections
por: Maravelia, Panagiota, et al.
Publicado: (2020)

Accelerated heterologous prime-boost adenovirus vector-based SIV vaccine in neonatal rhesus monkeys
por: Liu, J, et al.
Publicado: (2012)

Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8(+) T Cell Responses
por: Ring, Sandra S., et al.
Publicado: (2020)

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
por: He, Qian, et al.
Publicado: (2021)

Adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression
por: Ramirez-Valdez, Ramiro A., et al.
Publicado: (2023)

Heterologous Prime-Boost Vaccination with Inactivated Influenza Viruses Induces More Effective Cross-Protection than Homologous Repeat Vaccination
por: Bhatnagar, Noopur, et al.
Publicado: (2023)

Hepatitis C Virus Nonstructural 3/4A Protein Dampens Inflammation and Contributes to Slow Fibrosis Progression during Chronic Fibrosis In Vivo
por: Bansal, Ruchi, et al.
Publicado: (2015)

Broadly Reactive IgG Responses to Heterologous H5 Prime-Boost Influenza Vaccination Are Shaped by Antigenic Relatedness to Priming Strains
por: Wang, Jiong, et al.
Publicado: (2021)

Nucleoside-Modified mRNA Vaccines Protect IFNAR(–/–) Mice against Crimean-Congo Hemorrhagic Fever Virus Infection
por: Appelberg, Sofia, et al.
Publicado: (2022)

Brief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice
por: Aitken, Amelia S., et al.
Publicado: (2018)

Antibody response induced by the boost overdose during COVID-19 heterologous prime-boost vaccination strategy
por: Raposo, Francisco, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6j74i01gim4jdtg5rv83tss6n0